Sanyou Launches “oneClick+” Platform for Efficient Antibody Design

• Sanyou Biopharmaceuticals has launched the “Sanyou Innovative Intelligent Antibody Design oneClick+ Platform.”

• The platform integrates 90% of current antibody structures and offers four major systems for diverse antibody configurations.

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. has officially introduced its “oneClick+” platform, designed to enhance antibody development efficiency. This new platform integrates 90% of the mainstream antibody structures currently available, facilitating the design of various antibody configurations.

Launched recently, the “oneClick+” platform features four major systems: “IgG-like antibody”, “Nanobody (VHH)”, “Single-chain fragment variable antibody (ScFv)”, and “VHH+ScFv”. These systems encompass over 100 different configurations, broadening the scope of antibody design options.

Users can operate the platform in two ways. They can either input a complete antibody sequence for automatic alignment and physicochemical analysis or enter just the variable region sequence while selecting constant region sequences from the Sanyou Bio database. The platform then generates a detailed antibody report, including the physicochemical properties and structural diagram.

Dr. Guojun Lang, CEO of Sanyou Biopharmaceuticals, noted, “The ‘oneClick+’ platform marks a significant advancement in intelligent antibody design. It simplifies the design process, optimises operational efficiency, and enhances customer experience.”

The “oneClick+” platform aims to streamline antibody design by reducing complexities related to patent searches and software integration, providing a more straightforward tool for researchers and developers in the biopharmaceutical industry.